Corrigan O I, Timoney R F, Whelan M J
J Pharm Pharmacol. 1976 Sep;28(9):703-6. doi: 10.1111/j.2042-7158.1976.tb02840.x.
The dissolution properties of hydrochlorothiazide-PVP 10 000 mechanical mix and coprecipitate systems were qualitatively similar to those previously reported using hydroflumethiazide. Quantitative differences were dependent on the proportion of PVP present, its molecular weight and method of incorporation. Cumulative urinary excretion data from test capsule preparations showed that bioavailability was enhanced by the presence of PVP. However, the degree of enhancement was less than that expected from constant surface area disc rate studies. Dissolution tests on the capsule formulations, using the U.S.P. basket stirrer assembly, did not correlate with in vivo results. Using the Levy beaker method and a stirring speed of 40 rev min-1, good correlation between amount dissolved in 30 min and amount excreted in urine after 24 h was obtained. The dissolution tests revealed that PVP retards the initial dissolution from capsule dosage forms, probably by retarding deaggregation and dispersion of drug particles.
氢氯噻嗪 - PVP 10000机械混合物及共沉淀物体系的溶出特性在质量上与先前报道的氢氟噻嗪体系相似。定量差异取决于PVP的存在比例、其分子量及加入方法。测试胶囊制剂的累积尿排泄数据表明,PVP的存在提高了生物利用度。然而,提高程度低于恒定表面积圆盘速率研究预期的程度。使用美国药典篮式搅拌器组件对胶囊制剂进行的溶出试验与体内结果不相关。采用利维烧杯法及40转/分钟的搅拌速度,可得到30分钟内溶解量与24小时后尿中排泄量之间的良好相关性。溶出试验表明,PVP可能通过延缓药物颗粒的解聚和分散来延缓胶囊剂型的初始溶出。